1/13
09:03 am
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.
Medium
Report
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.
1/13
07:17 am
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/12
07:20 am
lxeo
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy [Yahoo! Finance]
High
Report
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy [Yahoo! Finance]
1/12
07:00 am
lxeo
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
High
Report
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
1/8
07:00 am
lxeo
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
Medium
Report
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
12/27
07:51 am
lxeo
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline [Yahoo! Finance]
Low
Report
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline [Yahoo! Finance]
12/25
07:22 pm
lxeo
Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
Low
Report
Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
12/22
08:05 am
lxeo
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/22
07:30 am
lxeo
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/20
07:27 am
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Low
Report
Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
12/17
05:02 pm
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Medium
Report
Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
12/15
05:52 pm
lxeo
Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight [Yahoo! Finance]
Low
Report
Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight [Yahoo! Finance]
12/11
08:07 am
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.
Low
Report
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.
12/10
08:45 am
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Lexeo Therapeutics (NASDAQ:LXEO) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/9
06:08 pm
lxeo
Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript [Seeking Alpha]
Low
Report
Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript [Seeking Alpha]
12/4
08:00 am
lxeo
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
Medium
Report
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
12/1
09:06 am
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.
High
Report
Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.
11/20
08:07 am
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.
Medium
Report
Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.
11/8
01:13 am
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at
Wall Street
Medium
Report
Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at
Wall Street
11/6
05:01 pm
lxeo
Lexeo Therapeutics: Behind The Rebound [Seeking Alpha]
Low
Report
Lexeo Therapeutics: Behind The Rebound [Seeking Alpha]
11/5
07:19 pm
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.
Low
Report
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.
11/5
07:36 am
lxeo
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
Medium
Report
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
11/3
01:09 pm
lxeo
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/26
06:18 am
lxeo
Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise [Yahoo! Finance]
Medium
Report
Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise [Yahoo! Finance]
10/21
09:44 am
lxeo
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions [Globe and Mail, The (Toronto, Canada)]
Low
Report
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions [Globe and Mail, The (Toronto, Canada)]